It has now retraced around 60% of it's recent gain. That's about all she wrote IMO. We might see a retest of $74 again, or even a drop to $72-$73 breifly, but all those greedy longs on the sidelines waiting for $70 or less will likely be dissapointed.
Samsung came out with a weaker than expected June qtr, citing slowing smartphone sales. Earnings were hurt by around 20%. How much will this affect SYNA bottom line going forward ? thanks
bergy. GPRE paid 35% in taxes, while PEIX won't be paying taxes. That means for PEIX to have the same $.82 qtr equivlent to GPRE, it has to make around $1.25.
In the Mar qtr they only had 16M shares, and paid no taxes. The $.77 would have been $1.40 if they still had 16M fd shares and paid no taxes in the June qtr ! Also compare this $.77 adjusted with a stock price of $18.50 with GPRE which just posted $.82, but with a stock price of $39 ! Also next qtr should be much better, as margins have improved substantially with the price of corn being at $3.60.
If they had only 16M shares like they did in the Mar qtr, and paid no taxes, they would have posted $1.40. In addition, their peer GPRE just reported $.82 for the June qtr, and the stock is selling for $39 vs PEIX $18.50 ! These were great numbers for the June qtr, and the Sept qtr will be better yet, as margins will be significantly higher with corn at $3.60. The stock is worth $30 all day long.
Yea, it went down 2%. By the way Kelly, it appears there were start up costs from Madera in the $.77 number. Do you see that ?
Short some ? What are you talking about ? If Madera start up costs were in the $.77 number, that means they would have posted more if we back them out, not less ! Maybe someone will bring it up on the CC/
bergucb- good points. If it turns out that Madera start up costs, or some one time costs were the culprit, then earnings & EPS should be adjusted up for that.
going forward 12 months in my opinion. I can't believe SYNA is selling at only a 10 PE going forward despite saying that their revenue growth over the next year is expected to go up by around 25%. Historically SYNA has sold for a 15 PE going forward, and I see no reason to not give it at least that now, given the strong revenue growth guidence. $110-$130 is a reasonable target IMO.
Rediculous not to be up more, after they beat the street by $.63 ! They made $5.35 EPS for the first six months, and margins are higher now than they were then. I see $3.25+ for the Sept qtr, and as much in the Dec qtr. If corn harvest comes in good again, and the ethanol mandate is positive for ethanol companies, then we could see more like $180 IMO.
lurker- where are you getting revenue estimates of $400M by 2020, and why only a 2x valuation ?
Warning label is being used by the big boys to get in on the cheap, and let out their short buddies. They know that the Iron boosting ability of Zerenex is a huge positive & has allowed 90% of the patients in clinical studies to get off their Iron suppliments. They know there were absoluately zero problems with " Iron overload ". I hope the CEO will clear thigs up at the conference today.
poorman- You will be poorer yet with that kind of reasoning
1) Insider sold as an automatic transaction to pay his taxes, and he had no discretion as to the timing of it.
2) Short interest was 21M on 8/29 but we don't know what it is now since FDA approval. Maybe news leaked to the shorts about the warning label- who knows. Either way, the shorts look to be in trouble in my view, especially with the potential use of Zerenex for a huge additional revenue stream from patients with early stage renal disease. That market in fact will likely triple or more the revenues they will make from treating CKD patients on dyalisis.
3) It is short term investors & traders that have gone. Long term investors with half a brain realize that the warning label has no meaning except to tell doctors to monitor iron levels while on Zerenex. In fact the ability of Zerenex to increase iron levels is a huge positive(as attested by nephrologists all over the world), and will enable a high % or those on iron suppliments to get off them.
4) Ferric Citrate in the form over the counter is far different in both surface area and dissolution than Zerenex. That's why the drug was FDA approved as a totally different entity. It works in a different way, and is hugely more effective. In fact more affective than any phosphate binder on the market today.
Darn right, it's not about the warnings. However it's not about huge doubts over whether KERX can market the drug either in my view. Every nephrologist thats chimed in on Zerenex has said it's by far the best phosphate binder out there, especially since in addition it can be substituted for costly Iron suppliment regiments as well. It worked for 90%+ in clinical trials to get CKD patients off their Iron suppliments, and will likely show the same high % in real practice.
In addition of course, as we all know, the market for the drug possibly to be used in early stage renal disease is huge, and dwarfs the market for Zerenex for CKD. With such unreal potential, there is no way that money will be an issue, and in fact KERX may fast become a buyout target. No, I think without a doubt that what we are seeing with KERX down 25%+ since FDA approval is pure manipulation in order for Institutions to get in on the cheap, and let the shorts out at the same time. Simple as that.